Laboratory of Biomarkers and Genomics of Neurodegeneration
R&D > Laboratories >Laboratory of Biomarkers and Genomics of Neurodegeneration-Prof. Roy Alcalay >>
Our Vision
To decipher the complex genomic basis of Parkinson's disease and other neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), dementia ataxia and Creutzfeldt-Jakob disease (CJD). To better understand the molecular and cellular mechanisms of neurodegeneration, identify biomarkers, and to assist in delaying or even in preventing these diseases.
Contact Us
Primary Investigators
Prof. Roy , Alcalay MD MS , Lab PI
Chief, Movement Disorders Division; Neurological Institute
Director, Laboratory of Biomarkers and Genomics of Neurodegeneration
Email: royal@tlvmc.gov.il
Mali Gana Weisz, PhD,Lab manager
Phone: +97236973628
+972526969464
Email: maligw@tlvmc.gov.il
Address
Sammy Ofer Building 10th Floor.
Tel Aviv Sourasky Medical Center
6 Weizmann St. Tel Aviv 64239 Israel
Research
Establish a large biospecimen repository of people affected by neurological disorders (Parkinson’s disease, CJD, dementia with Lewy bodies and early onset dementia) and their relatives who are at-risk to study the genetics and cellular mechanisms of the disease. |
Gallery
Our Team
Current Staff
- Prof. Roy Alcalay, MD, MS
- Mali Gana Weisz, PhD
- Orly Goldstein, PhD
- Tal Glinka, MSc
- Yael Shimshon, MSc
- Liat Freidlin, BSc.
- Shachar Shani, PhD student
Past Staff
- Prof. Avi Orr-Urtreger
- Anat Bar-Shira, PhD
- Ziv Gan-Or, MD-PhD
Current funding
Highlighted Publications
Goldstein O, Gana-Weisz M, Nefussy B, Vainer B, Nayshool O, Bar-Shira A, Traynor BJ, Drory VE, Orr-Urtreger A. Neurobiol Aging. 2018 Apr; 64:160.e1-160.e7. |
Bregman N, Kavé G, Mirelman A, Thaler A, Gana Weisz M, Bar-Shira A, Orr-Urtreger A, Giladi N, Shiner T. Alzheimer Dis Assoc Disord. 2019 Jul-Sep;33(3):279-281. |
Goldstein O, Kedmi M, Gana-Weisz M, Twito S, Nefussy B, Vainer B, Fainmesser Y, Abraham A, Nayshool O, Orr-Urtreger A, Drory VE. J Neurol Sci. 2019 Jul 15;402:62-68. (Last two authors equal contribution). |
Goldstein O, Gana-Weisz M, Cohen-Avinoam D, Shiner T, Thaler A, Cedarbaum JM, John S, Lalioti M, Gurevich T, Bar-Shira A, Mirelman A, Giladi N, Orr-Urtreger A. Mol Genet Metab. 2019 Dec;128(4):470-475. |
More Publications >>
A novel mutation in TARDBP segregates with amyotrophic lateral sclerosis in a large family with early onset and fast progression. Goldstein O, Kedmi M, Gana-Weisz M, Nefussy B, Vainer B, Fainmesser Y, Drory VE, Orr-Urtreger A. Amyotroph Lateral Scler Frontotemporal Degener. 2020 May;21(3-4):280-285. |
A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson’s Disease. Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Cedarbaum JM, Orr-Urtreger A, Mirelman A, Thaler A. Mov Disord. 2020; 35(7):1249-1253. |
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients. Alcalay RN, Wolf P, Chiang MSR, Helesicova K, Zhang XK, Merchant K, Hutten SJ, Scherzer C, Caspell-Garcia C, Blauwendraat C, Foroud T, Nudelman K, Gan-Or Z, Simuni T, Chahine LM, Levy O, Zheng D, Li G, Sardi SP; Parkinson’s Progression Markers Initiative (Collaborator Orr-Urtreger A). Ann Clin Transl Neurol. 2020 Oct;7(10):1816-1830. |
Biochemical markers for severity and risk in GBA and LRRK2 Parkinson’s disease. Thaler A, Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Cedarbaum JM, Orr-Urtreger A, Shenhar-Tsarfaty S, Mirelman A. J Neurol. 2021 Apr;268(4):1517-1525. |
Goldstein O, Gana-Weisz M, Casey F, Meltzer Fridrich H, Yaacov O, Waldman YY, Lin D, Mordechai Y, Zhu J, Cullen PF, Omer N, Shiner T, Thaler A, Bar-Shira A, Mirelman A, John S, Giladi N, Orr-Urtreger A. J Genet Genomics. 2021 Jan 20;48(4):341-345. |
Goldstein O, Gana-Weisz M, Attar R, Bar-Shira A, Lederkremer M, Shiner T, Thaler A, Mirelman A, Giladi N, Orr-Urtreger A. Molecular Genetics and Metabolism 2021 May;133(1):109-112. |
Less Publications >>
The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews. Shiner T, Mirelman A, Rosenblum Y, Kavé G, Weisz MG, Bar-Shira A, Goldstein O, Thaler A, Gurevich T, Orr-Urtreger A, Giladi N, Bregman N. J Alzheimers Dis. 2021;80(3):1221-1229. |
R869C mutation in molecular motor KIF17 gene is involved in Dementia with Lewy Bodies. Goldstein O, Gana-Weisz M, Shiner T, Attar R, Mordechai Y, Waldman YY, Bar-Shira A, Thaler A, Gurevich T, Mirelman A, Giladi N, Orr-Urtreger A. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2021 Jun 4;13(1):e12143. |
C9orf72-G4C2 Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis. Kobo H, Goldstein O, Gana-Weisz M, Bar-Shira A, Gurevich T, Thaler A, Mirelman A, Giladi N, Orr-Urtreger A.Genes (Basel). 2021 Aug 5;12(8):1210. |
Novel variants in genes related to vesicle-mediated-transport modify Parkinson’s disease risk. Goldstein O, Gana-Weisz M, Banfi S, Nigro V, Bar-Shira A, Thaler A, Gurevich T, Mirelman A, Giladi N, Alcalay RN, Orr-Urtreger A.Mol Genet Metab. 2023 May 12;139(2):107608. doi: 10.1016/j.ymgme.2023.107608 |
Shani S, Goldstein O, Gana-Weisz M, Bar-Shira A, Thaler A, Gurevich T, Mirelman A, Giladi N, Alcalay RN, Orr-Urtreger A. Parkinsonism Relat Disord. 2023 Apr 20;111:105398. doi: 10.1016/j.parkreldis.2023.105398. |
